Time course of disease characteristics in patients with severe allergic asthma starting treatment with omalizumab

Ann Allergy Asthma Immunol. 2022 Apr;128(4):468-469. doi: 10.1016/j.anai.2022.01.020. Epub 2022 Jan 24.

Authors

Todor A Popov¹, Diana Hristova², Tanya Z Kralimarkova², Tihomir B Mustakov², George H Christoff³

Affiliations

¹ University Hospital Sv Ivan Rilski, Clinic of Occupational DIseases, Sofia, Bulgaria. Electronic address: tedpop@rtb-mul.com.
² Alexander's University Hospital, Clinic of Allergology, Sofia, Bulgaria.
³ Faculty of Public Health, Medical University-Sofia, Sofia, Bulgaria.

PMID: 35085820
DOI: 10.1016/j.anai.2022.01.020

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Humans
Hypersensitivity*
Omalizumab / therapeutic use
Treatment Outcome

Substances

Anti-Asthmatic Agents
Omalizumab

Associated data

EudraCT/2015-002834-30